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Although the importance of LDL cholesterol lowering is widely recognized, the impact of the cholesterol-
lowering pattern on the atherosclerosis remains unclear. Here, we used cholestyramine in apolipoprotein
E deﬁcient mice in two different regimens to induce a see-saw shaped or a sustained cholesterol
reduction, with the trough of cholesterol comparable. After 12 weeks-treatment, a sustained cholesterol
reduction exhibited a smaller atherosclerotic area. Moreover, we observed a correlation between the area
under the curve of plasma cholesterol and the atherosclerotic area. These results suggest that the sus-
tained cholesterol reduction is beneﬁcial for preventing the progression of atherosclerosis in cholesterol
lowering therapy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Lowering plasma LDL cholesterol (LDL-C) levels by pharma-
ceutical agents including statin have been shown to decrease
subsequent cardiovascular events (1). Recently, the Improved
Reduction of Outcomes: Vytorin Efﬁcacy International Trial
(IMPROVE-IT), the combination treatment with simvastatin and
ezetimibe showed a further reduction of LDL-C levels than simva-
statin monotherapy, and led to further reduction in cardiovascular
events (2). This growing evidence also reinforces ‘the lower, the
better’ theory for LDL-C reduction.
The inhibitors for proprotein convertase subtilisin/kexin type 9
(PCSK9) have recently emerged on the market as a novel treatment
of high LDL-C. Anti-PCSK9 antibodies have shown stronger reduc-
tion of LDL-C levels than with any other types of LDL-C lowering
agents. Thus, based on ‘the lower the better’ theory, it is expected
that PCSK9 inhibitors reduce cardiovascular events signiﬁcantly.
However it should be noted that the cholesterol-lowering pattern
appeared to be different due to the different dose regime, and is
largely dependent on dose interval based on the results of two
independent anti-PCSK9 antibodies (3,4). In particular, adminis-
trating anti-PCSK9 antibody every 4 weeks showed a see-saw
shaped LDL-C reduction, while administrating anti-PCSK9co.jp (Y. Masuda).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).antibody every 2 weeks showed a sustained LDL-C reduction.
Whether these differences inﬂuence the rates of cardiovascular
events reduction remains to be clear as is also discussed previously
(3).
In the present study, we investigated the effect of the
cholesterol-lowering pattern on the progression of atherosclerosis
in mice using cholestyramine. Male apolipoprotein E deﬁcient
(apoE KO) mice aged 13 weeks old at initiation of the study were
used in the present study. They were purchased from Charles River
Laboratories Japan, Inc. All experimental procedures were per-
formed in accordance with the in-house guideline of the Institu-
tional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd.
Western diet (WD) was purchased from Japan SLC, Inc. Cholestyr-
amine was purchased from SigmaeAldrich Corporation. For mea-
surement of plasma Total Cholesterol (TC) and Triglyceride (TG)
levels, blood was collected from the tail vein. Concentration of
plasma TC and TG was measured by Cholesterol E-test Wako and
Triglyceride E-test Wako (Wako Pure Chemical Industries, Ltd.)
respectively. Preparation of histological sections from the aortic
roots was essentially made according to a technique as described
previously (5). The heart was ﬁxed in Mildform® 10N (Wako Pure
Chemical Industries, Ltd.) at 4 C and embedded using parafﬁn.
Cross-sections throughout the entire aortic root area were stained
by Elastica Masson, and then, the atherosclerotic lesion area
was determined with software (NDP.view2). The results are rep-
resented as the average of four sections each separated by 50 mm.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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bodies (Santa Crus Biotechnology sc-19991) and the immuno-
stained areas in the sections were quantiﬁed using image analysis
software (Meta Morph).
A Tukey's test was performed regarding the atherosclerotic
lesion area and the macrophage area. Pearson's correlation coefﬁ-
cient (r) between the area under the curve of plasma TC (TC-AUC)
and the atherosclerotic lesion area or macrophage area was
calculated. Statistical analysis was performed with SAS System
Release 9.2.
In the present study, mice were maintained with WD for 2
weeks, followed by measurement of plasma TC, TG levels and body
weight. Thereafter, the mice continued to be maintained onWD for
12 weeks and were allocated into three groups based on these
factors. Group 1 was the control group, group 2 was treated with
1.5% and 3% cholestyramine where the treatment was switched
every 2 weeks to induce a see-saw shape cholesterol-lowering
pattern, and group 3 was treated with 3% cholestyramine to
induce a sustained cholesterol-lowering pattern. Previous studies
showed WD fed apoE KO mice showed an increase of plasma TC
levels where most of the content of TC was non-HDL (6,7). More-
over, cholestyramine treatment for apoE KO mice reduced only
non-HDL (8), thereforewe followed TC and TG levels every 2weeks.
The transition of plasma TC is shown in Fig. 1A. As expected,
mice in group 2 exhibited a see-saw shaped cholesterol reduction,
whereas mice in group 3 exhibited a sustained cholesterol reduc-
tion. The lowest points of cholesterol in both groups were notFig. 1. The transition of plasma lipids proﬁle. Apolipoprotein E deﬁcient mice were
maintained on western diet with or without cholestyramine for 12 weeks (Group 1;
control, Group 2; 1.5% or 3% cholestyramine treatment where treatment was switched
every 2 weeks, and Group 3; 3% cholestyramine treatment). Plasma (A) total choles-
terol (TC) and (B) triglyceride (TG) levels were measured every 2 weeks. The results are
represented as mean ± S.E.M, N ¼ 10 (Group 1), 7 (Group 2) and 8 (Group 3)
****P < 0.0001, statistically signiﬁcant compared to Group 3 (Tukey's test).statistically different (2 week; P ¼ 0.2174, 6 week; P ¼ 0.2619, 10
week; P ¼ 0.9155). Cholestylamine treatment also reduced plasma
TG levels compared to that of control group (group 2; 6 week;
P ¼ 0.0066, 10 week; P ¼ 0.0026, group 3; 6 week; P ¼ 0.0007, 10
week; P ¼ 0.0134). On the other hands, plasma TG levels were not
different between mice in group 2 and group 3 at any points (2
week; P ¼ 0.9384, 4 week; P ¼ 0.8696, 6 week; P ¼ 0.7282, 8 week;
P ¼ 0.9946, 10 week; P ¼ 0.7199, 12 week; P ¼ 0.9409).
To evaluate whether cholesterol-lowering pattern, as indicated
above, affects the progression of atherosclerosis, we thenmeasured
the atherosclerotic lesion area. As shown in Fig. 2A, cholestyramine
treatment lowered the area of atherosclerotic lesion signiﬁcantly
compared to vehicle treatment (group 2: P ¼ 0.008, group 3:
P < 0.0001). Notably, a sustained cholesterol reduction exhibited a
statistically signiﬁcant smaller lesion area compared to a see-saw
shaped cholesterol reduction (P ¼ 0.0356). In addition to athero-
sclerotic lesion area, we also assessed the area of macrophage of
atherosclerotic lesion as a marker of lesion vulnerability (Fig. 2B).
We observed that cholestyramine treatment reduced the macro-
phage area compared to the control group (group 2: P ¼ 0.0002,
group 3: P < 0.0001) and there was also a trend, although not
statistically signiﬁcant, that a sustained cholesterol reduction
showed a smaller macrophage area compared to a see-saw shaped
cholesterol reduction (P ¼ 0.5495). Then we measured TC-AUC of
each mouse to evaluate the correlation with the atherosclerotic
lesion area. As shown in Fig. 3, we observed a high correlation
between TC-AUC and the atherosclerotic lesion area (r ¼ 0.79), and
a correlation between TC-AUC and macrophage area (r ¼ 0.75).
In the present study, we created two cholesterol-lowering
pattern using cholestyramine, which reduces cholesterol levels by
decreasing intestinal cholesterol absorption based on binding to
bile acid (9). In this study, we observed plasma TG reduction in the
cholestyramine treatment group compared to the control group as
consistent with a previous report (8). Although we observed an
unexpected rebound of TG levels at week 4, notably, plasma TG
levels were comparable at any point between group 2 and group 3
(Fig. 1B). Therefore, the TG reduction is unlikely to account for the
difference in the atherosclerotic lesion area between group 2 and
group 3. Regarding the atherosclerotic lesion area, we observed the
correlation with TC-AUC as it was reported in other report (10). As
for the relationship between macrophage area and TC-AUC, we
observed a similar trend to the correlation of TC-AUC and the
atherosclerotic lesion area, suggesting that maintaining lower
cholesterol levels prevents from lesion fragility. Daily administra-
tion of statins and biweekly LDL-C apheresis is effective in
decreasing cardiovascular events (11). Above treatment showed
maximum reduction following LDL-C apheresis, after that reduced
LDL-C rapidly return towards baseline levels. Although this evi-
dence clearly demonstrates the signiﬁcance of cholesterol lowering
even in the case that the maximum lowering is transient, our re-
sults suggest that the importance of the maintenance of lower
cholesterol levels also needs to be considered to further prevent the
lesion progression. In addition, our results also suggest that
cholesterol measurements at multiple time points are helpful to
estimate the effect of cholesterol lowering drug on the cardiovas-
cular events risk in clinic with high probability. The ongoing
FOURIER trial and ODYSSEY Outcomes trial may provide deﬁnitive
evidence on the inﬂuence of LDL-C lowering pattern on cardio-
vascular events (12,13).
There are some limitations in our study. First, we used apoE KO
mice, whereas a complete lack of apoE is rare in humans. Further-
more the apoE KO mice were maintained with WD to promote
atherosclerosis in this study, hence the cholesterol levels of mice in
this study were much higher than that of dyslipidemia patients.
Second, we used cholestyramine to manipulate the cholesterol
Fig. 2. The impact of the cholesterol-lowering pattern on the atherosclerosis. (A) After 12 weeks of cholestyramine treatment, the hearts were isolated and atherosclerotic lesion
areas were stained with Elastica Masson. (B) The atherosclerotic lesion areas were measured. (C) The macrophages in the lesion were stained with anti-LAMP2 antibody and stained
areas were measured. The results are represented as mean ± S.E.M, N ¼ 10 (Group 1; control), 7 (Group 2; 1.5% or 3% cholestyramine treatment where treatment was switched every
2 weeks) and 8 (Group 3; 3% cholestyramine treatment). ***P < 0.001, ****P < 0.0001, statistically signiﬁcant compared to the control group (Tukey's test). #P < 0.05, statistically
signiﬁcant compared to the 1.5% or 3% cholestyramine treatment exchanged every 2 weeks group (Tukey's test).
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Fig. 3. The relation between the area under the curve of plasma total cholesterol (TC-
AUC) and (A) the atherosclerotic lesion area or (B) macrophage area. TC-AUC of each
mouse from 0 week to 12 week was calculated. A Pearson's correlation coefﬁcient (r)
was calculated.
Y. Masuda et al. / Journal of Pharmacological Sciences 132 (2016) 271e274274levels of these mice, however statins are most widely used to
evaluate the association between LDL-C levels and cardiovascular
events (1), and the ongoing FOURIER trial and ODYSSEY Outcomes
trial are being used anti-PCSK9 antibody. These agents all reduce
LDL-C by the up-regulation of hepatic LDL receptor levels (14) and
although cholestyramine is reported to decrease LDL-C partially
through the up-regulation of LDL receptor levels (15), initial targets
of these agents are different, therefore precise mechanisms that
reduce LDL-C would be not exactly same. Thus, the effects of these
agents on the atherosclerosis might be different.
In summary, a sustained cholesterol reduction lowered the
progression of atherosclerosis compared to a see-saw shaped
cholesterol reduction although the lowest point of cholesterol be-
tween two groups was not different. Regarding anti-PCSK9 anti-
bodies treatment, several treatment regimen options may be
provided considering patients' compliance, however, our results
suggest that the sustained cholesterol reduction could be beneﬁcial
for preventing the progression of atherosclerosis and the reduction
of future cardiovascular events risk.Conﬂict of interest
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